Next Article in Journal
Staphylococcal Superantigen (TSST-1) Mutant Analysis Reveals that T Cell Activation Is Required for Biological Effects in the Rabbit Including the Cytokine Storm
Next Article in Special Issue
Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy
Previous Article in Journal / Special Issue
SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model
Toxins 2010, 2(9), 2258-2271; doi:10.3390/toxins2092258
Review

Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy

1,* , 2
 and
1
1 Department of Paediatric Orthopaedics, Centre for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany 2 Centre for physiotherapy and neurorehabilitation, Berlin, Germany
* Author to whom correspondence should be addressed.
Received: 23 July 2010 / Revised: 24 August 2010 / Accepted: 26 August 2010 / Published: 27 August 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
View Full-Text   |   Download PDF [947 KB, uploaded 27 August 2010]   |   Browse Figures
SciFeed

Abstract

The treatment of children with cerebral palsy with Botulinum toxin A injections is well established, safe and effective. However, a standardized injection strategy is still missing and the used dosage has escalated over the years. In the recent past, the recommended dosages in Europe were, however, reduced due to a better understanding of the relationship between dosage, severe side effects and the kind of anesthesia used. To combine safety and efficacy, the trend tends to a lower dosage, but combined with a more specific selection of injected muscles. The treatment of these key-muscles takes into account the best support for motor development to attain each individual motor milestone.
Keywords: botulinum toxin A; cerebral palsy; CP; multi-level treatment; key-muscle concept botulinum toxin A; cerebral palsy; CP; multi-level treatment; key-muscle concept
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Placzek, R.; Siebold, D.; Funk, J.F. Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy. Toxins 2010, 2, 2258-2271.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert